Correlation Analysis Between Prolonged Chemotherapy Interval Time And Prognosis In Lymphoma Patients

Objectives: To analyze the prolongation of the average chemotherapy interval time of lymphoma patients and its possible affecting factors.Moreover,to explore its influences on the prognosis of lymphoma patients.Methods: The general condition and clinical data of lymphoma patients who were first treated and had regular chemotherapies from January 2010 to December2019 in the first hospital of Lanzhou University were retrospectively analyzed.The included patients were grouped according to the prolongation of the average interval time of chemotherapy.Its influence on the prognosis of the patients and related factors were analyzed by using statistical methods.Results: In this study,the median average prolongation of the chemotherapy interval time for the 25 HL patients is 3（0-20.71）days.At the same time,the median average prolongation of the chemotherapy interval time for the 46 DLBCL patients is4.27（0-36.67）days.Univariate and multivariate analysis indicated that comorbidities or complications were the independent risk factor for prolonging chemotherapy interval time in DLBCL patients（p <0.05）.The DLBCL patients were divided into three groups according to the average prolonged interval time of chemotherapy: ≤0days group,>0 and <5 days group,≥5 days group.The 2-year OS rates of the three groups of patients were（100±0）%、（84.2±8.4）%、（50.3±11.8）%;and the 2-year PFS rates of the three groups were（100±0）%、（73.7±10.1）%、（50.8±11.8）%,with both statistically significant（p=0.017 and p=0.019）.After pairwise comparison,it was found that the OS and PFS time of the patients in the ≥5 days group were significantly lower than those in the group whose average prolonged interval time of chemotherapy was ≤0 days,and the differences were statistically significant（p<0.0167）.Multivariate analysis indicated that for DLBCL patients,prognostic stratification was the factor influencing OS and PFS,and the prolonged average chemotherapy interval time ≥5 days was the factor influencing OS（all p<0.05）.For the patients of the HL group,we did not find the affecting factors to the prolongation of the chemotherapy interval time through univariate and multivariate analysis.And we also did not find a correlation between the prolongation of the chemotherapy interval time and the prognosis of the HL patients.Conclusions:1.For DLBCL patients,the prolongation of the average chemotherapy interval time ≥5 days was the adverse factor influencing prognosis.2.Comorbidities or complications were independent factors affecting the prolongation of chemotherapy interval time.